Get the Stockscreener App
1.95
1.56%
0.03
After Hours:
1.94
-0.01
-0.51%
Ocugen Inc stock is traded at $1.95, with a volume of 12.70M.
It is up +1.56% in the last 24 hours and up +4.84% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.92
Open:
$1.98
24h Volume:
12.70M
Relative Volume:
1.70
Market Cap:
$639.40M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-8.636
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-14.85%
1M Performance:
+4.84%
6M Performance:
+28.29%
1Y Performance:
+172.84%
1-Day Range:
$1.93
$2.11
1-Week Range:
$1.79
$2.30
52-Week Range:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.95 | 629.56M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Shares Drop as Eye Disease Gene Therapy Shows Delays in Phase II Trial - Bitget
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail
Noble Capital raises Ocugen stock price target on phase 2 results By Investing.com - Investing.com Australia
Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410 - Citeline News & Insights
OCGN: HC Wainwright & Co. Raises Price Target to $10.00, Maintai - GuruFocus
Noble Capital raises Ocugen stock price target on phase 2 results - Investing.com
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout - Yahoo Finance
H.C. Wainwright raises Ocugen stock price target on gene therapy data - Investing.com
HC Wainwright Increases Ocugen (NASDAQ:OCGN) Price Target to $10.00 - MarketBeat
10 best high-risk penny stocks to buy right now - MSN
why-did-dpro-stock-crash-after-hours-today - Stocktwits
Ocugen (OCGN) Has A Healthy Cash Position For 2026 - Insider Monkey
Ocugen (OCGN) Shares Tumble After Phase 2 Trial Data Release - GuruFocus
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months - MarketBeat
Ocugen (NASDAQ:OCGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Ocugen’s Tumultuous Chapter: Earnings, Strategies, and Market Reactions - StocksToTrade
Ocugen Reports Positive Phase 2 Data for OCU410 Therapy - TipRanks
Ocugen’s Strategic Directions Amid Economic Challenges - timothysykes.com
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (NASDAQ: OCGN) reports strong Phase 2 OCU410 results in geographic atrophy - Stock Titan
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
OCU410 Phase II data show significant reduction in lesion size at 12 months - The Pharma Letter
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA - Traders Union
Ocugen stock falls 5% despite positive gene therapy trial data - Investing.com
Ocugen (OCGN) Reports Promising Phase 2 Results for Gene Therapy OCU410 - GuruFocus
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce? - Stocktwits
Ocugen stock falls on trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 31% lesion reduction in gene therapy trial By Investing.com - Investing.com Canada
Ocugen reports 31% lesion reduction in gene therapy trial - Investing.com
OCGN: OCU410 reduced lesion growth by 31% at 12 months in Phase 2, with no serious safety issues - TradingView
Ocugen, Inc. Reports Phase 2 Results for OCU410 Showing 31% Reduction in Geographic Atrophy Lesion Growth After 12 Months - Quiver Quantitative
One-shot gene therapy cut eye-lesion growth 31% in dry AMD trial - Stock Titan
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge - Yahoo Finance
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen a new buy at Canaccord on pipeline for retinal diseases - MSN
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks - Yahoo Finance
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - Ocugen, Inc.
Ocugen (NASDAQ:OCGN) Shares Gap UpShould You Buy? - MarketBeat
Ocugen's Dose Dilemma: A Risky Bet on Gene Therapy Clarity - Bitget
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy - Bitget
Ocugen To Present Full Phase 2 ArMaDa Data Fo... - Benzinga
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT - GlobeNewswire
Ocugen, Inc.(NasdaqCM: OCGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ocugen Secures Crucial Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Earnings Risk: Will Ocugen Inc stock recover after earnings2026 Review & Safe Entry Momentum Tips - baoquankhu1.vn
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):